Citigroup Inc Ngm Biopharmaceuticals Inc Transaction History

Citigroup Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.17 - $1.92 $117,108 - $192,178	100,093 Added 1354.81%	107,481 $170,000
Q4 2023 Feb 09, 2024	BUY	$0.6 - $1.31 $3,799 - $8,296	6,333 Added 600.28%	7,388 $6,000
Q3 2023 Nov 09, 2023	SELL	$1.05 - $3.37 $15,638 - $50,192	-14,894 Reduced 93.39%	1,055 $1,000
Q2 2023 Aug 10, 2023	BUY	$2.44 - $4.53 $34,733 - $64,484	14,235 Added 830.51%	15,949 $41,000
Q1 2023 May 11, 2023	SELL	$3.72 - $5.4 $1,595 - $2,316	-429 Reduced 20.02%	1,714 $6,000
Q4 2022 Feb 09, 2023	SELL	$3.41 - $12.93 $27,331 - $103,633	-8,015 Reduced 78.9%	2,143 $10,000
Q3 2022 Nov 10, 2022	SELL	$12.59 - $17.67 $34,723 - $48,733	-2,758 Reduced 21.35%	10,158 $133,000
Q2 2022 Aug 10, 2022	BUY	$10.58 - $17.5 $26,206 - $43,347	2,477 Added 23.73%	12,916 $165,000
Q1 2022 May 12, 2022	SELL	$13.81 - $18.6 $93,894 - $126,461	-6,799 Reduced 39.44%	10,439 $159,000
Q4 2021 Feb 10, 2022	SELL	$17.26 - $22.02 $3.81 Million - $4.86 Million	-220,589 Reduced 92.75%	17,238 $305,000
Q3 2021 Nov 10, 2021	BUY	$20.15 - $26.19 $4.79 Million - $6.23 Million	237,827 New	237,827 $5 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.